6
MNiSW
58.21
ICV
RESEARCH PAPER
 
CC BY-NC-ND 3.0
 
 

Evaluating the incidence of cytomegalovirus and rubella antibodies in women of childbearing age

Barbara Rajtar 2  ,  
 
1
Studenckie Koło Naukowe przy Zakładzie Wirusologii, Uniwersytet Medyczny w Lublinie
2
Zakład Wirusologii, Uniwersytet Medyczny w Lublinie
MONZ 2017;23(3):185–188
KEYWORDS:
TOPICS:
ABSTRACT:
Introduction.:
During the course of pregnancy, women are particularly prone to microbial infections that are not potentially life-threatening; however, they may pose a serious threat to developing foetus. A woman can prevent infection either by being in contact with the pathogen during childhood or by acquiring immunity through vaccination. The viruses that are threatening to pregnant women include, among others, cytomegalovirus and rubella virus. These pathogens may cause congenital infections that can lead to a number of birth defects or even stop the development of the foetus. Therefore, an early diagnosis and prevention is crucial as far as pregnant women are concerned. Objectives. The aim of the study was to evaluate cytomegalovirus and rubella antibody titers in women of childbearing potential.

Objectives.:
The aim of the study was to evaluate cytomegalovirus and rubella antibody titers in women of childbearing potential.

Material and methods:
In order to assess the titer of IgG class antibodies to cytomegalovirus and rubella in women of childbearing age, 42 blood serum samples collected from women aged between 20–25 years were examined. Determination of the presence and quantity of the specific antibodies was performed by utilising the NovaLisaTM sets and ELISA method.

Results:
The study indicated the presence of IgG antibodies to cytomegalovirus in 61.9% of the examined women and IgG antibodies to rubella virus in 97.6% of those examined.

Conclusions:
1. Approximately 40% of the examined had no antibody against cytomegalovirus, which indicates the absence of a previous contact with CMV. 2. A high degree of immunization against rubella was observed among women at child-bearing age.

CORRESPONDING AUTHOR:
Barbara Rajtar   
Zakład Wirusologii, Uniwersytet Medyczny w Lublinie, ul. W. Chodźki 1, 20-093 Lublin, Polska
 
REFERENCES:
1. Milewska-Bobula B, Lipka B. Cytomegalia wrodzona – postępy w roz¬poznawaniu i leczeniu. Przegl Epidemiol. 2009; 63: 79–83
2. https://talk.ictvonline.org/taxonomy/ (dostęp: 06.07.2017).
3. Działo J, Deptuła W. Systematyka wirusów kręgowców – aktualne dane. Kosmos Problemy Nauk Biologicznych. 2010; 59(3–4): 435–449.
4. Miszczak D, Słońska A, Golke A, Cymerys J. Strategie przetrwania herpeswirusów – latencja i apoptoza. Postepy Hig Med Dosw. 2013; 67: 276–287.
5. Dzeciątkowski T, Wróblewska M. Zakażenia wirusem cytomegalii oraz ich diagnostyka laboratoryjna u biorców komórek krwiotwórczych. Diagn Lab. 2015; 51(1): 59–62.
6. Collier L, Oxford J. Wirusologia. Wyd. 2. PZWL, 2001.
7. Yamamoto R, Ishii K, Shimada M, Hayashi S, Hidaka N, Nakayama M i wsp. Significance of maternal screening for toxoplasmosis, rubella, cytomegalovirus and herpes simplex virus infection in cases of fetal growth restriction. J Obstet Gynaecol Res. 2013; 39: 653–657.
8. Zagólski O, Smarzyńska A. Słuchowe potencjały wywołane z pnia mózgu u niemowląt z wrodzonymi zakażeniami TORCH. Otoryno-larngologia. 2003; 2(4): 185–188.
9. Wiczyńska-Zając A, Ejmocka-Ambroziak A. Zakażenia cytomega¬lowirusem w ciąży. Borgis – Nowa Medycyna. 2000; 8. http://www. czytelniamedyczna.pl/1427,zakazenia-cytomegalowirusem-w-ciazy. html (dostęp: 06.07.2017).
10. Paradowska-Stankiewicz I, Rogalska J, Polkowska A. Różyczka w Polsce w 2014 roku. Przegl Epidemiol. 2016; 70(3): 341–348.
11. Dunal M, Trzcińska A, Siennicka J. Wirus cytomegalii – problem zakażeń wrodzonych. Post Mikrobiol. 2013; 52(1): 17–28.
12. Willame A, Blanchard-Rohner G, Combescure C, Irion O, Posfay-Barbe K, Martinez de Tejada B. Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study. Int J Environ Res and Public Health. 2015; 12(12): 15285–15297.
13. Pokorska-Śpiewak M, Niezgoda A, Gołkowska M, Czech-Kowalska J, Gruszfeld D, Dobrzańska A i wsp. Rekomendacje postępowania w zaka¬żeniach wirusem cytomegalii (CMV). Zalecenia Polskiego Towarzystwa Epidemiologów i lekarzy chorób zakaźnych. Przegl Epidemiol. 2016; 70(2): 297–310.
14. Margioula-Siarkou C, Kalogiannidis I, Petousis S, Prapa S, Dagklis T, Mamopoulos A i wsp. Cytomegalovirus, Toxoplasma gondii and Rubella Vertical Transmission Rates According to Mid-trimester Amniocente¬sis: A Retrospective Study. Int J Prev Med. 2015; 6: 32.
15. Gelemanović A, Dobberpuhl K, Krakar G, Patarčić I, Kolčić I, Polašek O. Host genetics and susceptibility to congenital and childhood cytome¬galovirus infection: a systematic review. Croat Med J. 2016; 57: 321–330.
16. Schleiss MR. Cytomegalovirus vaccines under clinical development. J Virus Erad. 2016; 2(4): 198–207.
17. Farra A, Pagonendji M, Manikariza A, Rawago D, Ouambita-Mabo R, Guifara G i wsp. Epidemiology of primary rubella infection in the Central African Republic: data from measles surveillance, 2007–2014. BMC Infect Dis. 2016; 16: 505.
18. Getahun M, Beyene B, Gallagher K, Ademe A, Teshome B, Tefera M i wsp. Epidemiology of rubella virus cases in the pre-vaccination era of Ethiopia, 2009–2015. BMC Public Health. 2016; 16: 1168.
eISSN:2084-4905
ISSN:2083-4543